ストックスクリーナーアプリを入手
5.65
1.92%
-0.09
前日終値:
$5.74
開ける：
$5.74
24時間の取引高:
42,265
Relative Volume:
0.23
時価総額：
$34.96M
収益：
$2.19M
当期純損益:
$-24.19M
株価収益率:
-0.6568
EPS:
-8.6017
ネットキャッシュフロー:
$-82.94M
1週間 パフォーマンス:
+0.54%
1か月 パフォーマンス:
-12.44%
6か月 パフォーマンス:
-42.90%
1年 パフォーマンス:
+0.72%
1日の値動き範囲:
$5.60
$5.75
1週間の範囲:
$5.52
$6.11
52週間の値動き範囲:
$5.12
$13.69
Aligos Therapeutics Inc Stock (ALGS) Company Profile
名前
Aligos Therapeutics Inc
セクター
電話
(800) 466-6059
住所
ONE CORPORATE DR., 2ND FLOOR, SOUTH SAN FRANCISCO
Compare ALGS vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ALGS
Aligos Therapeutics Inc
|
5.65 | 35.52M | 2.19M | -24.19M | -82.94M | -8.6017 |
VRTX
Vertex Pharmaceuticals Inc
|
438.32 | 110.64B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
636.73 | 66.53B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
825.13 | 50.27B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
297.21 | 39.45B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
153.90 | 32.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Aligos Therapeutics Inc Stock (ALGS) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-03-19 | 再開されました | Jefferies | Buy |
| 2025-08-18 | 再開されました | H.C. Wainwright | Buy |
| 2024-08-19 | 開始されました | H.C. Wainwright | Buy |
| 2023-01-06 | アップグレード | Jefferies | Hold → Buy |
| 2023-01-06 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2022-03-23 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2022-01-07 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2022-01-06 | ダウングレード | Jefferies | Buy → Hold |
| 2021-09-09 | 開始されました | SVB Leerink | Outperform |
| 2021-05-17 | 再開されました | Piper Sandler | Overweight |
| 2020-11-10 | 開始されました | Cantor Fitzgerald | Overweight |
| 2020-11-10 | 開始されました | JP Morgan | Overweight |
| 2020-11-10 | 開始されました | Jefferies | Buy |
| 2020-11-10 | 開始されました | Piper Sandler | Overweight |
すべてを表示
Aligos Therapeutics Inc (ALGS) 最新ニュース
Aligos Therapeutics (ALGS) Showcases Promising Data at EASL Cong - GuruFocus
Hepatitis B data: 40% on Aligos drug reach HBsAg level used for cure regimens - Stock Titan
Aligos Therapeutics Presents Positive Data at the EASL Congress 2026 - Investing News Network
Aligos Therapeutics Presents Positive Phase 1 Data for Pevifoscorvir Sodium at EASL Congress 2026, Suggesting Reduced cccDNA Reservoir in Chronic HBV Patients - Quiver Quantitative
Aligos Therapeutics Presents Positive Data at the EASL Congress 2026 - GlobeNewswire Inc.
Cantor Fitzgerald Initiates Aligos Therapeutics(ALGS.US) With Buy Rating, Announces Target Price $20 - Moomoo
ALGS Initiated Coverage by Cantor Fitzgerald -- Rating Set to Ov - GuruFocus
ALGS News | ALIGOS THERAPEUTICS INC (NASDAQ:ALGS) - ChartMill
Lawrence M. Blatt discloses 5.1% stake in Aligos Therapeutics (ALGS) - Stock Titan
Aligos (ALGS) Delivers Q1 2026 Beat — EPS $-2.21 vs $-2.27 ExpectedSocial Trade Signals - Newser
Woodline Partners reports 4.4% stake in Aligos Therapeutics (NASDAQ: ALGS) - Stock Titan
Aligos Therapeutics Announces Ten Abstracts Accepted for Presentation at EASL Congress 2026 - Quiver Quantitative
Aligos Therapeutics Announces Ten Abstracts Accepted for Presentation at the EASL Congress 2026 - Weekly Voice
Liver disease drug data: Aligos secures 10 EASL 2026 slots - Stock Titan
TradingKey - TradingKey
What you need to know before buying Aligos (ALGS) (Investor Concern) 2026-05-08Crowd Consensus Signals - newser.com
The operating leverage hidden in Aligos (ALGS) results | Q1 2026: EPS Exceeds ExpectationsTarget Revision - Newser
Aligos Therapeutics (NASDAQ:ALGS) Surges After Hours on Q1 Earnings Beat - ChartMill
Aligos Therapeutics Reports Recent Business Progress and First Quarter 2026 Financial Results - Investing News Network
China HBV license adds cash as Aligos (NASDAQ: ALGS) faces going‑concern risk - Stock Titan
Aligos lands FDA Fast Track and a $25M China deal for HBV drug - Stock Titan
Earnings Preview: ALGS to Report Financial Results Post-market on May 07 - Moomoo
How Aligos Therapeutics Inc. (ALGS) Affects Rotational Strategy Timing - Stock Traders Daily
Aligos Therapeutics Inc expected to post a loss of $2.22 a shareEarnings Preview - TradingView
Aligos Therapeutics to Announce 1st Quarter 2026 Financial Results on May 7, 2026 - Investing News Network
Biotech Aligos will post first-quarter results after markets close May 7 - Stock Titan
[ARS] Aligos Therapeutics, Inc. SEC Filing - Stock Titan
Aligos Therapeutics says China pact puts HBV drug in focus amid trial updates - MSN
Aligos Therapeutics (Nasdaq: ALGS) details ESPP, auditor and pay votes - Stock Titan
Aligos’ licensing deal in China broadens trial scope, secures immediate $25m - MLex
Is Aligos (ALGS) overbought or oversold? (Drifts Higher) 2026-04-27Retail Flow - Newser
Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
This micro cap biotech stock is tracking its biggest intraday gains in 11 months – here’s why a China deal has retail buzzing - MSN
(ALGS) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Aligos Therapeutics (ALGS) Gets a Buy from H.C. Wainwright - The Globe and Mail
Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635 - Investing News Network
New Aligos hires get stock options for 10,700 shares under Nasdaq rule - Stock Titan
Aligos Therapeutics jumps on China licensing agreement - MSN
Deal Watch: First Quarter Posted High Volume, Dollar Value In Alliance Deals - Citeline News & Insights
Aligos (ALGS) Stock: Why Margin Improvement (Institutional Demand) 2026-04-22Short Term Trading - Cổng thông tin điện tử tỉnh Tây Ninh
Aligos Therapeutics Licenses Hepatitis B Drug Rights to Amoytop - TipRanks
Aligos Therapeutics (NASDAQ: ALGS) signs Hep B deal with up to $420M milestones - Stock Titan
Aligos (ALGS) Stock Volume Confirmation (Wavering) 2026-04-20Earnings Season - Cổng thông tin điện tử tỉnh Lào Cai
Aligos Therapeutics Inc (ALGS) 財務データ
収益
当期純利益
現金流量
EPS
0.67%
1.91%
大文字化:
|
ボリューム (24 時間):